Medicine, Money, and the Drug at the Center of the Storm
From Murder, Mysteries and Conspiracies with Glenn P Clinger III · · 16 min
This plays from the publisher's own server. We do not host a copy.
Description
A drug that failed to become the answer for Ebola suddenly became one of the most important treatments of the COVID era.
At the same time, cheap medications like hydroxychloroquine and ivermectin became deeply controversial, social-media platforms restricted certain treatment claims, and governments spent billions on newer pharmaceutical drugs.
Was this simply medicine evolving under extraordinary pressure—or did money, fear, and institutional power shape the treatments we were told to trust?
In Part Two of our COVID series, we examine the trials, the pricing, the competing treatments, and the unanswered questions that still fuel suspicion today.
Follow the evidence. Follow the money. Then decide for yourself.
Sources for this episode
The PALM Ebola trial, published in the New England Journal of Medicine, found the antibody therapies MAb114 and REGN-EB3 superior to the comparison treatments, and investigators stopped assigning new patients to the remdesivir and ZMapp groups after an interim analysis. New England Journal of Medicine (https://www.nejm.org/doi/full/10.1056/NEJMoa1910993?utm_source=chatgpt.com)
NIH documented the pre-COVID scientific rationale: the drug showed activity against MERS in rhesus monkeys, and NIH explicitly said those results supported testing against the emerging novel coronavirus. National Institutes of Health (https://www.nih.gov/news-events/news-releases/remdesivir-prevents-mers-coronavirus-disease-monkeys?utm_source=chatgpt.com) NIH subsequently reported reduced clinical disease and lung damage in SARS-CoV-2-infected rhesus monkeys treated early with the antiviral. National Institutes of Health (https://www.nih.gov/news-events/news-releases/antiviral-remdesivir-prevents-disease-progression-monkeys-covid-19?utm_source=chatgpt.com)
The first U.S. randomized controlled COVID treatment trial began in February 2020. National Institutes of Health (https://www.nih.gov/news-events/news-releases/nih-clinical-trial-remdesivir-treat-covid-19-begins?utm_source=chatgpt.com) The ACTT-1 results found faster recovery—approximately 10 days versus 15—and NIH emphasized recovery time as the principal demonstrated benefit. National Institutes of Health (https://www.nih.gov/news-events/news-releases/nih-clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19?utm_source=chatgpt.com)
The FDA's May 1, 2020 emergency authorization specifically stated that information on the drug's safety and effectiveness for hospitalized COVID patients remained limited while noting the clinical-trial evidence for faster recovery. U.S. Food and Drug Administration (https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment?utm_source=chatgpt.com)
The WHO Solidarity trial found little or no effect on overall mortality, initiation of ventilation, or hospitalization duration among hospitalized patients. World Health Organization (https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments/interim-results?utm_source=chatgpt.com)
For hydroxychloroquine, FDA records confirm an EUA was issued March 28, 2020 and revoked June 15, 2020 U.S. Food and Drug Administration (https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization-archived-information?utm_source=chatgpt.com) The RECOVERY randomized trial found 28-day mortality of 27.0% with hydroxychloroquine versus 25.0% with usual care. New England Journal of Medicine (https://www.nejm.org/doi/10.1056/NEJMoa2022926?utm_source=chatgpt.com)
For ivermectin, the FDA confirms it is an established human antiparasitic drug and that physicians can prescribe approved human medicines off-label in appropriate circumstances, while also stating that available clinical-trial data did not demonstrate effectiveness against COVID. U.S.…
Back to Murder, Mysteries and Conspiracies with Glenn P Clinger III · Report a problem